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Abstract
Background: Advances in our understanding of the molecular biology of colorectal cancer have fuelled the search for novel
molecular prognostic markers to complement existing staging systems. Markers assessed in combination may perform better
than those considered individually. Using high-throughput tissue microarray technology, we describe the prognostic value of
combined p53 / Bcl-2 status in colorectal cancer.
Patients and methods: Tumour samples from 462 patients who underwent elective surgery to resect a primary colorectal
cancer between 1994 and 2000 (mean follow-up of 75 months) were assembled in tissue microarray format. Clinico-pathological
data including tumour grade, stage, vascular invasion status along with disease specific survival data has been collected
prospectively. Immunohistochemical analysis of p53 and Bcl-2 expression was performed using antibodies DO-7 (p53) and 124
(Bcl-2), and results correlated with known clinico-pathological variables and outcomes.
Results: Abnormal nuclear p53 accumulation and Bcl-2 overexpression were detected in 221/445 (49.6%) and199/437 (45.5%)
tumours respectively, with a significant inverse correlation between the two markers (p = 0.023). On univariate analysis no
correlations were found between either marker and standard clinico-pathological variables, however nuclear p53 expression
was associated with a significantly reduced survival (p = 0.024). Combined analysis of the two markers indicated that 112/432
(24.2%) cases displayed a p53(-)/Bcl-2(+) phenotype, this occurring more frequently in earlier stage tumours. Kaplan-Meier
analysis revealed a significant survival advantage in these p53(-)/Bcl-2(+) tumours compared with the remaining cases (p =
0.0032). On multivariate analysis using the Cox proportional hazards model, neither p53 expression nor Bcl-2 expression alone
were of independent prognostic significance, however the combined p53(-)/Bcl-2(+) phenotype was significantly associated with
a good prognosis in this series (HR 0.659, 95%CI 0.452–0.959, p = 0.029).
Conclusion: Patient stratification by combined p53 / Bcl-2 phenotype provides stage-independent prognostic information in
colorectal cancer. Specifically, that up to a quarter of patients display a good prognosis p53(-)/Bcl-2(+) phenotype. This may
indicate a more clinically indolent phenotype and a subset of patients for whom less aggressive adjuvant treatment appropriate.
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Background
Colorectal cancer kills approximately 500 000 people
worldwide each year [1], thus treatments which produce
only modest improvements in survival may have an enor-
mous health impact. Current practice is to base therapeu-
tic decisions and prognostic advice on clinico-
pathological data, however within conventional staging
groups many genetic and molecular tumour subtypes
exist. This heterogenicity of tumour genotypes accounts
for much of the observed variation in recurrence rates and
clinical responses to available therapies.
Advances in our understanding of the molecular biology
of colorectal cancer have fuelled the search for novel
molecular prognostic markers with which to complement
existing staging systems. Applied to clinical practice, these
putative markers could be used to identify groups of
patients with differing relative risks of recurrence and
improve patient stratification for adjuvant treatment.
Immunohistochemical studies in colorectal cancer have
tended to investigate expression of individual proteins in
relation to prognosis, and relatively few studies have
focused on the analysis of multiple markers in combina-
tion. However, one such combination which may be of
value in colorectal cancer is the combined p53 / Bcl-2 phe-
notype, as suggested by Manne et al, who described the
p53/Bcl-2 phenotype of 134 patients with Dukes stage A-
D tumours, finding that this combination gave independ-
ent prognostic information which was superior to that of
either marker on its own [2]. The same group have subse-
quently shown in a larger cohort of 234 patients with
tumours of the distal colo-rectum that combined p53/Bcl-
2 analysis may provide stronger prognostic information
than nodal status [3]. Other researchers have reported
similar findings in differing groups of colorectal cancer
patients [4,5], with the p53(-)/Bcl-2(+) subset appearing
to define a group of patients who appear to have a pro-
longed survival, although this has not always retained
independence on multivariate analysis [6,7]. Alterna-
tively, it has been suggested that opposing p53(+)/Bcl-2(-
) phenotype defines a particularly poor prognosis subset
[8], or that Bcl-2 positivity in combination with either
p53, p21 or mdm-2 confers a good prognosis [9].
Since its first description in 1998, tissue microarray (TMA)
analysis [10] has been employed for the immunohisto-
chemical analysis of target protein expression in a wide
range of primary tumour types. Initial fears that the
reduced amount of individual tumour tissue analysed
using this technique might not be representative of the
tumour as a whole appear largely unfounded [11], and the
strengths of this approach lie in its ability to provide a
rapid turnover of results from very large patient cohorts,
whilst reducing variability in experimental conditions and
reducing costs [12]. Two previous studies have utilised tis-
sue microarray technology to investigate the combination
of p53/Bcl-2 in rectal cancer. In the first, Hoos et al, stud-
ied 100 patients with lymph-node negative rectal cancer,
and found an increased number of deaths in the patients
with p53(+)/Bcl-2(-) tumors (7/33, 21.2%) compared
with the p53(-)/Bcl-2(+) group (2/13, 15.4%) [13], and a
recent study of 269 patients with Dukes stage A-D rectal
cancer reported a lower rate of metastatic disease in p53(-
)/Bcl-2(+) tumours, with p53(+)/Bcl-2(-) tumours show-
ing a worse outcome [14].
The aim of the present study was to investigate the prog-
nostic significance of the combined p53/Bcl-2 phenotype
in a large scale, representative sample of colorectal cancers
using tissue microarrays, in order to determine the poten-
tial utility of this combination of molecular markers in
guiding treatment of patients in the UK.
Patients and methods
Patients and specimens
The study population comprised 462 patients undergoing
elective surgery for a single, non-metachronous histologi-
cally proven primary colorectal cancer at University Hos-
pital Nottingham between 1st  January 1994 and 31st
December 2000. Data regarding tumour site, stage, histo-
logical type and tumour grade have been recorded pro-
spectively for these patients. Only patients with lymph
node positive disease were routinely treated with adjuvant
chemotherapy, comprising 5-flurouracil and folinic acid.
The original histopathological slide sets and pathological
reports for all cases were obtained from the hospital
archives, and reviewed to confirm the diagnosis and the
accuracy of existing data. However, in a minority of cases
only very limited slide sets were available and the full clin-
ico-pathological dataset was incomplete. In addition, we
did not attempt to ascertain the vascular invasion status of
tumours where this information had not been previously
recorded.
Follow-up data regarding the date and cause of death for
this cohort of patients has been provided prospectively by
the UK Office for National Statistics. Follow-up was calcu-
lated from the date of resection of the primary tumour,
and all surviving cases were censored for survival analysis
at 31st December 2003. Disease specific survival was used
as the primary end-point. The Local Research Ethics Com-
mittee granted approval for the study.
Preparation of the tissue microarray
Tissue microarrays were constructed as described previ-
ously [10]. 5 µm haematoxylin and eosin (H&E) stained
slides were used to identify and mark out representative
areas of viable tumour tissue. 0.6 mm needle core-biop-
sies from the relevant areas of corresponding paraffin-World Journal of Surgical Oncology 2005, 3:47 http://www.wjso.com/content/3/1/47
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embedded blocks were then placed at defined coordinates
in the recipient paraffin array blocks using a manual
arrayer (Beecher Instruments, Sun Prarie, WI). Array
blocks were constructed at a density of 80–150 cores per
array. Analysis of each marker was performed on a single
core from each tumour. This typically shows over 90%
concordance with conventional whole section analysis of
tumour markers and has been validated previously [11].
Immunohistochemical methods
Immunohistochemistry was performed using a standard
avidin-biotin peroxidase method with p53 mAb clone
DO-7 (1:20 dilution, Dako Ltd, Ely, UK), and Bcl-2 mAb
clone 124 (1:50, Dako Ltd, Ely, UK). Briefly, 5 µm array
sections were deparaffinised with xylene, rehydrated
through graded alcohol and immersed in methanol con-
taining 0.3% hydrogen peroxide for 10 minutes to block
endogenous peroxidase activity. Heat induced epitope
retrieval consisting of 20 minutes microwave treatment in
pH 6.0 citrate buffer was necessary with the DO-7 mAb.
Endogenous avidin/biotin binding was blocked using an
avidin/biotin blocking kit (Vector Labs, USA) and sections
were treated with 100 µl of normal swine serum (NSS) for
10 min to block non-specific binding of the primary
antibody.
Test sections were incubated with 100 µl of primary anti-
body for 1 hr at room temperature. Positive control tissue
comprised whole sections of human tonsil. Primary anti-
body was omitted from negative control sections, which
were incubated in NSS. After washing with TBS sections
were incubated with 100 µl of biotinylated goat anti-
mouse/rabbit immunoglobulin (Dako Ltd, Ely, UK)
diluted 1:100 in NSS for 30 min, followed by 100 µl of
pre-formed streptavidin-biotin/horseradish peroxidase
(HRP) complex (Dako Ltd, Ely, UK) for 60 min at room
temperature. Staining was finally visualised using 3, 3'-
Diaminobenzidine tetrahydrochloride (DAB, Dako Ltd,
Ely, UK).
Evaluation of staining
Evaluation of the staining was carried out by two observ-
ers (NFSW and ZM) blinded to the clinico-pathological
data, with a consensus decision in all cases. For each anti-
gen tumours were classified in two groups with the
defined cut-off values of: p53 overexpression if >10%
tumour nuclei stained, irrespective of staining intensity,
and Bcl-2 overexpression if cytoplasmic staining (any
intensity) was identified in >30% of the tumour cells.
These values were determined from previous studies using
the same reagents in colorectal cancer [13], although it
has recently been shown in a meta-analysis that when
using the DO-7 antibody, reducing the cut-off value to 1%
of the nuclei stained does not alter the outcome of subse-
quent survival analysis [15]. In order to further investigate
the significance of the combined p53 / Bcl-2 phenotypes,
the individual staining patterns for these antigens were
combined and then analysed as an additional group.
Statistical methods
All statistical analyses were performed using the SPSS
package (version 11 for Windows, SPSS Inc., Chicago, IL).
Associations between categorical variables were examined
using cross tabulation and the Pearson chi-square test for
categorical variables. Kaplan-Meier curves were derived in
order to assess disease-specific survival, and the signifi-
cance of differences in disease-specific survival between
groups was calculated using the log-rank test. Complete
outcome data was available for all but one patient in the
study. Patients whose deaths related to their colorectal
cancer were considered in the disease-specific survival cal-
culations. However, patients who died from postoperative
complications (deaths within 1 month of the date of sur-
gery), and patients with carcinoma in-situ (pTis tumors)
were excluded from the survival analyses. Deaths resulting
from non-colorectal cancer related causes were censored
at the time of death. Multivariate analysis using the Cox
proportional-hazards model was employed to determine
hazard ratios and identify variables with independent
prognostic significance in this cohort. In all cases P values
<0.05 were considered statistically significant.
Results
Clinico-pathological data
The arrayed tumours were found to be broadly represent-
ative of the spectrum of colorectal cancer encountered in
the UK (Table 1). The median age at the time of surgery
was 72 years, consistent with a median age at diagnosis of
colorectal cancer of 70–74 years in the UK [16]. At the
time of censoring for data analysis 49% of patients had
died from their disease, 37% were still alive and 14% were
deceased from non-colorectal cancer related causes. 38
deaths occurred within one month of surgery. The median
length of follow-up available for surviving patients was 75
months (range 36–116). The overall median five-year dis-
ease-specific survival for the cohort was 58 months, which
is comparable with the approximately 45% five-year sur-
vival seen for colorectal cancer in the UK [17].
Antigen expression
The observed frequencies of expression for p53 and Bcl-2
are shown in table 2. Although it has previously been
stated that the number of cores uninterpretable due to tis-
sue loss or damage in tissue microarray studies may
exceed 20–30% of the total, this was not observed in the
current study. The highest number of uninterpretable
cases (30 cases / 6.5% of total) was seen when the results
for p53 and Bcl-2 were combined. Representative exam-
ples of positive and negative staining for each antigen are
shown in figure 1.World Journal of Surgical Oncology 2005, 3:47 http://www.wjso.com/content/3/1/47
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p53 expression
p53 in its wild-type form is undetectable by conventional
immunohistochemical methods, due to its short half-life.
In contrast, most mutations in the p53 gene lead to
expression of a stable protein product which accumulates
in the nucleus and is detected by the DO-7 antibody. In
this study overexpression of p53 was detected in 221/445
tumours (49.6%). On univariate analysis no associations
were found between p53 expression and clinico-patholog-
ical variables including tumour grade, stage and the pres-
ence of extramural vascular invasion, however a
significant relationship was noted between p53 expres-
sion and disease specific survival. On Kaplan-Meier anal-
ysis (figure 2), patients with p53(-) tumours
Table 1: Clinico-pathological variables for the patient cohort (n = 462).
Age (years) Median 72
Range 57–89
Gender Male 266 (58%)
Female 196 (42%)
Status Alive 169 (37%)
Dead (colorectal cancer related) 228 (49%)
Dead (non-colorectal cancer causes) 64 (14%)
Unknown 1
Histological type Adenocarcinoma 392 (85%)
Mucinous carcinoma 51 (11%)
Columnar carcinoma 4 (1%)
Signet ring carcinoma 7 (1%)
Unknown 8 (2%)
Histological grade Well differentiated 29 (6%)
Moderately differentiated 353 (77%)
Poorly differentiated 71 (15%)
Unknown 9 (2%)
Tumour site Colon 238 (52%)
Rectal 181 (39%)
Unknown 43 (9%)
TNM stage 0 (Tis)3  ( 1 % )
16 9  ( 1 5 % )
2 174 (38%)
3 155 (33%)
45 4  ( 1 2 % )
Unknown 7 (2%)
Extramural vascular invasion Negative 224 (48%)
Positive 128 (28%)
Unknown 110 (24%)
Table 2: Frequencies of immunohistochemical expression of p53 and Bcl-2.
Antigen Number (%) positive (high) Number (%) negative (low) Number (%) missing
p53 221 (47.8) 224 (48.5) 17 (3.7)
Bcl-2 199 (43.1) 238 (51.5) 25 (5.4)
p53 (-) / Bcl-2 (+) combination 112 (24.2) 320 (69.3) 30 (6.5)World Journal of Surgical Oncology 2005, 3:47 http://www.wjso.com/content/3/1/47
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demonstrated a significantly longer mean disease specific
survival (DSS) of 76 (95% CI 69–83) months, as com-
pared with a mean DSS of 64 (95% CI 57–71) months in
patients with p53(+) tumours (p = 0.0240).
Bcl-2 expression
Overexpression of Bcl-2 protein was detected in the cyto-
plasm of 199/437 evaluable tumours (45.5%). In
contrast, no nuclear expression of Bcl-2 was observed.
Although no strong associations between Bcl-2 expression
and clinico-pathological variables were noted, there was a
trend on univariate analysis towards increased cytoplas-
mic accumulation of Bcl-2 in moderate and poorly differ-
entiated tumours compared with well differentiated
tumours (p = 0.076). On Kaplan-Meier analysis, no asso-
ciation was found between Bcl-2 expression and survival
(p = 0.0865, figure 3).
p53(-) / Bcl-2(+) phenotype
Comparing results for both Bcl-2 and p53, a significant
reciprocal pattern of expression was seen (table 3, p =
0.023). Combining the results for these two markers, a
total of 112/432 tumours (25.9%) displayed the p53(-) /
Bcl-2(+) phenotype. A trend was noted toward a higher
prevalence of this phenotype in earlier stage tumours,
with a prevalence of 33.9%, 26.3%, 24.1% and 14.3% in
TNM stage I-IV tumours respectively (p = 0.078). Addi-
tional strong correlations were noted between the p53(-)
/ Bcl-2(+) phenotype and DSS on univariate analysis (p =
0.004), and on Kaplan-Meier analysis, with a mean DSS of
A & B show cores from a tumour demonstrating positive staining for p53 (A), and negative staining for Bcl-2 (B) Figure 1
A & B show cores from a tumour demonstrating positive staining for p53 (A), and negative staining for Bcl-2 (B). C & D show 
cores from a p53 negative (C) / Bcl-2 positive (D) tumour. All at x20 original magnification.World Journal of Surgical Oncology 2005, 3:47 http://www.wjso.com/content/3/1/47
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84 (95%CI 75–92) months in patients with p53(-) / Bcl-
2(+) tumours compared with a mean survival of 65 (95%
CI 59–71) months in the remaining patients (figure 4) (p
= 0.0032).
Multivariate analysis
HRs for individual markers
A multivariate analysis of factors influencing survival was
performed using the Cox proportional hazards model.
Analysis included all available cases. Of the conventional
clinico-pathological variables analysed, significant inde-
pendent prognostic value was demonstrated only for
TNM stage, and for vascular invasion status. In contrast,
neither p53 expression, nor Bcl-2 expression alone were
found to be independent markers of prognosis. Consider-
ing the combined p53(-) / Bcl-2(+) phenotype, this was
found to have independent prognostic value, conferring a
significant survival advantage as compared with the other
possible combinations of p53 / Bcl-2 expression (table 4).
Discussion
Previous studies have suggested that combined p53 and
Bcl-2 immunostaining may provide useful prognostic
information in colorectal cancer; however these conclu-
sions have been derived from varying study populations,
with heterogeneous methodology and limited sample
sizes. To our knowledge no previous study has
investigated these findings in such a large, representative
cohort of patients from the UK. Using widely validated
antibodies and established techniques, our results indi-
cate that patient stratification by combined p53/Bcl-2
phenotype provides tumour stage-independent
Kaplan-Meier plot for disease specific survival, p53 (+) vs p53 (-) tumours (n = 408) Figure 2
Kaplan-Meier plot for disease specific survival, p53 (+) vs p53 (-) tumours (n = 408).
Logrank=5.09 ,P=0.0240
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prognostic information; specifically, that a subset of up to
a quarter of colorectal cancer patients display a good prog-
nosis p53(-)/Bcl-2(+) phenotype.
In line with previous studies, we found no positive corre-
lations between expression of the individual markers and
our clinico-pathological data [18]. However, as has been
the case previously [19], we noted significant reciprocity
of p53 and Bcl-2 expression. Saleh et al, reported an asso-
ciation between Bcl-2 expression and lower p53 levels, a
lower mean Ki-67 labelling index and favourable his-
topathological parameters [20]. Similarly, Popescu et al,
demonstrated reciprocal expression of Bcl-2 and p53
mRNA in samples from 19 colorectal cancer metastases
Kaplan-Meier plot for disease specific survival, Bcl-2 (+) vs Bcl-2 (-) tumours (n = 400) Figure 3
Kaplan-Meier plot for disease specific survival, Bcl-2 (+) vs Bcl-2 (-) tumours (n = 400).
Table 3: Co-expression of p53 with Bcl-2.
Number (%) p53 (+) Number (%) p53 (-)
Number (%) Bcl-2 (+) 129 (29.8) 106 (24.5)
Number (%) Bcl-2 (-) 87 (20.1) 111 (25.6)
Logrank=2.94, p=0.0865
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Kaplan-Meier plot for disease specific survival comparing p53 (-) / Bcl-2 (+) tumours with alternative phenotypes (n = 396) Figure 4
Kaplan-Meier plot for disease specific survival comparing p53 (-) / Bcl-2 (+) tumours with alternative phenotypes (n = 396).
Table 4: Cox multivariate analysis.
Variable Category OR 95% CI p value
TNM stage I 1 <0.001
II 1.427 0.758–2.689
III 3.170 1.728–5.816
IV 22.070 11.309–43.068
Unknown 2.895 0.640–13.102
Vascular invasion status Negative 1 <0.001
Positive 2.156 1.525–3.047
Unknown 1.221 0.798–1.869
p53/Bcl-2 status Non- p53(-) / Bcl-2 (+) 1 0.029
P53(-) / Bcl-2 (+) 0.659 0.452–0.959
Logrank=8.71, p=0.0032
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[21], however, other studies have failed to confirm this
finding [22]. Although not statistically significant, we also
noted a trend towards a higher prevalence of the good
prognosis p53(-)/Bcl-2(+) subgroup in earlier stage
tumours, in agreement with the findings of Gouissa et al,
who demonstrated a trend for the p53(-)/Bcl-2(+) pheno-
type to be associated with lymph node negative tumours
in a study of 108 colorectal adenocarcinomas [22].
Two recent papers have systematically reviewed the evi-
dence for a prognostic role of p53 expression in colorectal
cancer and illustrate some of the difficulties in interpret-
ing the available literature. In the first, Anwar et al,
described 35 studies (24 using immunohistochemical
methods) in which p53 was found to be predictive of a
worse outcome and 24 papers (16 employing IHC) found
no association. In total only 4 of these studies included a
comparable number of patients to ours, with 39 studies
reporting on <150 cases [23]. In the second review Munro
et al, included 168 articles, reporting survival outcomes on
a pool of over 18 000 patients. In this large review factors
such as sources of heterogeneity between studies, the
effect of publication bias and various assumptions con-
cerning the techniques used for assessing p53 abnormali-
ties led them to limit their conclusion to the fact that in
patients with a better underlying prognosis, abnormal
p53 has an adverse effect on outcome [15].
It appears logical that combined analysis of p53 with Bcl-
2 should prove greater than the sum of its parts, as the p53
protein is known to regulate apoptosis via the Bcl-2/BAX
pathway. Native p53 inhibits Bcl-2 gene expression by
transcriptional activation of the pro-apoptotic gene BAX
[24]. Bcl-2 itself is a proto-oncogene, whose expression
varies in differing tissues. In the normal gastrointestinal
tract Bcl-2 expression has been detected in the basal cells
of crypts. Bcl-2 expression has also been described in the
majority (up to 85%) of colorectal adenomas, with
reduced expression on progression to invasive carcinoma
[25,26]. Despite the defined role of Bcl-2 protein in sup-
pression of apoptosis, in colorectal cancer the evidence
suggests that Bcl-2 expression is correlated with favoura-
ble parameters [27] and a better prognosis [28]. This may
be explained by the finding that although Bcl-2 inhibits
apoptosis it may also slow cell growth [29]. It has been
reported that Bcl-2 contains an anti-proliferative domain,
distinct from the domains required for its anti-apoptotic
activity [30], and also that Bcl-2 can be converted to a
BAX-like death effector by cleavage of a regulatory loop
domain by caspases [31]. Whatever the underlying biolog-
ical mechanism, in this study we have found that the com-
bination of positive cytoplasmic Bcl-2 expression and
negative nuclear p53 expression in colorectal cancer
defines a population of patients with a good prognosis,
indicating a clinically more indolent phenotype and a
subset of patients for whom less aggressive adjuvant treat-
ment is indicated.
Conclusion
The use of molecular prognostic markers which comple-
ment traditional clinico-pathological staging information
is not yet widespread in colorectal cancer, mainly due to
the lack of high quality prospective studies and concerns
regarding reproducibility and generalisation from existing
data [32]. In particular, quantitative scoring of immunos-
taining for practical/diagnostic purposes is a very difficult
affair and liable to much subjectivity. This is probably the
major reason why so few quantitative immunomarkers
have made their way into surgical pathology. These issues
need to be addressed if we are to improve on existing
prognostic criteria. However, our results suggest that anal-
ysis of p53 and Bcl-2 expression in colorectal cancer
patients may provide useful prognostic information.
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